Organovo Holdings Inc.

The global human liver model market is projected to grow at a CAGR of 14.04% from 2025 to 2030, driven by the increasing prevalence of liver diseases, advancements in organ printing technologies, and increased demand for liver cancer therapeutics.

Related tickers: MRK, ONVO.

Eli Lilly announced plans to acquire Organovo's FXR program and launched larger-dose vials of its weight loss drug Zepbound at lower prices, causing its stock to rise 2.6% despite a market downturn.

Related tickers: LLY, ONVO, NVOH, HIMS.